Adma Biologics reported $61.07M in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
Adma Biologics USD 61.07M 12.52M Mar/2026
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
Minerva Neurosciences USD -4.36M 1.71M Sep/2024
Novavax USD 19.36M 190.79M Dec/2025
Omeros USD -47.96M 7.39M Sep/2023
Takeda JPY 150.25B 297.88B Mar/2026